NCT06356012View on ClinicalTrials.gov

Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated with Imiquimod

PHASE4RecruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

April 2, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
HSIL, High-Grade Squamous Intraepithelial LesionsVaginal MicrobiomeBiomarkers
Interventions
DRUG

Imiquimod

Experimental group will be treated with 16 applications of imiquimod and subsequently LEEP.

PROCEDURE

Loop Electrosurgical Excision Procedure

Active comparator group will be treated with LEEP.

Trial Locations (1)

Unknown

RECRUITING

Barretos Cancer Hospital, Barretos

All Listed Sponsors
collaborator

Fundação de Amparo à Pesquisa do Estado de São Paulo

OTHER_GOV

collaborator

Farmoquimica S.A.

INDUSTRY

collaborator

Hospital de Cancer de Barretos - Fundacao Pio XII

OTHER

lead

Barretos Cancer Hospital

OTHER